KellyB.PendergrassMD

PubMed

• 8 citations
  First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
  Angelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass, Luca Malorni, Jasmine Lichfield, Miguel Martin> ;Breast. 2018 Apr 1
• 17 citations
  TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer
  Denise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky, David Drosick, Fred J. Kudrik, Linda D. Bosserman, Mark Keaton, Sharon A. Goble,...> ;Breast Cancer Research and Treatment. 2017 May 15
• 98 citations
  A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
  James B. Bussel, David J. Kuter, Louis M. Aledort, Craig M. Kessler, Adam Cuker, Kelly Pendergrass, Shande Tang, Joe McIntosh> ;Blood. 2014 Jun 19
• Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial.
  Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Ruk...> ;J. Natl. Cancer Inst.. 2014-01-01
• 14 citations
  Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology
  Sally Garnett, Miguel Martin, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Igor Bondarenko, Rustem Khasanov, Didier Verhoeven, Jose Luiz Pedrini, Iva Smirnova, Mik...> ;Breast Cancer Research and Treatment. 2013 Feb 3
• A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed...
  Moreau P, Palumbo AP, Stewart AK, Rajkumar V, Jakubowiak AJ, Halka K, Goranov S, Bumbea H, Pendergrass KB, Lupu A, Dimopoulos A, Rocafiguera AO, Gandhi JG, Mihaylov G,...> ;J. Clin. Oncol.. 2011-05-20
• PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diff...
  Leonard J, Reeves J, Ferhanoglu B, Doner KT, Eom H, Flinn IW, Raposo J, Chowhan NM, Suh C, Noga S, Tumyan G, Aung S, Hajdenberg J, Ulrich BK, Pendergrass KB, Mulligan ...> ;J. Clin. Oncol.. 2011-05-20
• 136 citations
  Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor...
  J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger, Robert A. Wolff, Katherine Lloyd-Salvant, György Bodoky, Kelly Pendergrass, William Be...> ;Journal of Clinical Oncology. 2011 May 20
• 432 citations
  Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer
  Angelo Di Leo, Guy Jerusalem, Lubos Petruzelka, Roberto Torres, Igor Bondarenko, Rustem Khasanov, Didier Verhoeven, Jose Luiz Pedrini, Iya Smirnova, Mikhail Lichinitse...> ;Journal of Clinical Oncology. 2010 Oct 20
• TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC).
  Gross M, Pendergrass K, Leitner S, Leichman G, Pugliese L, Silberman S> ;J. Clin. Oncol.. 2008-05-20
• Characterization of hyperglycemia, hypercholesterolemia, and hyperlipidemia in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-α.
  de Souza PL, Radulovic S, Beck J, Pendergrass K, Siddique N, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Hudes GR> ;J. Clin. Oncol.. 2008-05-20
• 20 citations
  Phase III, Double-Blind, Controlled Trial of Atamestane Plus Toremifene Compared With Letrozole in Postmenopausal Women With Advanced Receptor-Positive Breast Cancer
  Paul E. Goss, Igor N. Bondarenko, Georgiy Manikhas, Kelly Pendergrass, Wilson H. Miller, Peter Langecker, Dennis G Blanchett> ;Journal of Clinical Oncology. 2007 Nov 1
• Phase 3 study of atamestane + toremifene vs. letrozole in advanced breast cancer.
  Goss PE, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH, Blanchett D, Lang W, Langecker P> ;J. Clin. Oncol.. 2006-06-20
• A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and...
  Major P, Trarbach T, Lenz H, Kerr D, Pendergrass K, Douillard J, Chen B, Laurent D, Jacques C, Van Cutsem E> ;J. Clin. Oncol.. 2006-06-20
• 17 citations
  Aprepitant: an oral NK1 antagonist for the prevention of nausea and vomiting induced by highly emetogenic chemotherapy.
  Kelly Pendergrass, Richard Hargreaves, Kevin J. Petty, Alexandra D. Carides, Judith K. Evans, Kevin J. Horgan> ;Drugs of Today. 2004 Oct 1
• 266 citations
  Reduction of Cisplatin-Induced Emesis by a Selective Neurokinin-1–Receptor Antagonist
  Rudolph M. Navari, Rick R. Reinhardt, Richard J. Gralla, Mark G. Kris, Paul J. Hesketh, Ali Khojasteh, Hedy L. Kindler, Thomas H. Grote, Kelly Pendergrass, Steven M. G...> ;The New England Journal of Medicine. 1999 Jan 21
• 17 citations
  Options in the treatment of chemotherapy-induced emesis.
  Kelly Pendergrass> ;Cancer Practice. 1998 Sep 1
• 15 citations
  Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
  Mark G. Kris, Kelly Pendergrass, Rudolph M. Navari, Thomas H. Grote, A M Nelson, V Thomas, B B Ferguson, D S Allman, Barbara Pizzo, T W Baker, I J Fernando, S B Chernoff> ;Journal of Clinical Oncology. 1997 May 1
• 414 citations
  Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
  Sandra M. Swain, Fredrick S. Whaley, Miriam C. Gerber, Steven Weisberg, Martin York, Darcy V. Spicer, Stephen E. Jones, Scott Wadler, Ajit Desai, Charles L. Vogel, Jam...> ;Journal of Clinical Oncology. 1997 Apr 1
• 18 citations
  Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.
  Thomas H. Grote, Pineda Lf, Figlin Ra, Kelly Pendergrass, Paul J. Hesketh, Karlan By, Reeves Ja, Porter Ll, Claude R. Benedict, William F. Hahne> ;The Cancer Journal from Scientific American. 1997 Jan 1
• 13 citations
  Randomized phase III Study of 5‐fluorouracil plus high dose folinic acid versus 5‐fluorouracil plus folinic acid plus methyl‐lomustine for patients with advanced color...
  Dennie V. Jones, Roger J. Winn, Barry W. Brown, B B A Lawrence Levy, Reginald P. Pugh, James L. Wade, Howard M. Gross, Kelly B. Pendergrass, Bernard Levin, James L. Ab...> ;Cancer. 1995 Nov 15
• 69 citations
  Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of...
  Thomas M. Beck, Paul J. Hesketh, Stefan Madajewicz, Rudolph M. Navari, Kelly Pendergrass, Eric P. Lester, J A Kish, W K Murphy, John D. Hainsworth, David R. Gandara> ;Journal of Clinical Oncology. 1992 Dec 1
• 117 citations
  A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associ...
  John D. Hainsworth, W. H. Harvey, Kelly Pendergrass, B Kasimis, D Oblon, G. G. Monaghan, D Gandara, Paul J. Hesketh, A Khojasteh, G Harker> ;Journal of Clinical Oncology. 1991 May 1
• 48 citations
  Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
  Thomas P. Miller, Steve Dahlberg, James K. Weick, Joseph C. Files, Harmon J. Eyre, Kelly Pendergrass, Richard I. Fisher> ;Journal of Clinical Oncology. 1990 Dec 1
• Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies....
  Cubeddu, L. X., Pendergrass, K., Ryan, T., York, M., Burton, G., Meshad, M., Galvin, D., Ciociola, A. A.> ;Am J Clin Oncol. 1994 Apr
• Join now to see all